Email This Article
Headlines & Perspectives
Biotech Mailbag: All About Alnylam
By
Adam Feuerstein
11/28/08 - 11:50 AM EST
The stock hasn't been this low since July 2007, but lung drug data could set it up for a rebound.
TheStreet Premium Services For Personal Service: 877-471-2967
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
ETF Profits:
Get money-making ideas from the hottest investment vehicle on the planet. Our experts show you how to play various ETF sectors to help pump-up your portfolio. Learn More
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn More| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 12,865.64 | 1,352.09 | 2,927.85 | 19.90 |
Oil *
117.43
|
|
UP
64.41 |
UP
9.45 |
UP
23.97 |
UP
0.21 |
10 Yr
1.99%
SPDR Gold
167.49
|
|
+0.50%
|
+0.70%
|
+0.83%
|
+1.07%
|
Data delayed 20 minutes |
Connect with TheStreet